Potential Utility of Radiopharmaceuticals in the Battle Against SARS-Cov-2 and COVID-19 Pandemic

被引:0
作者
Sager, Omer [1 ]
Dincoglan, Ferrat [1 ]
Demiral, Selcuk [1 ]
Beyzadeoglu, Murat [1 ]
机构
[1] Univ Hlth Sci Turkey, Gulhane Fac Med, Dept Radiat Oncol, Ankara, Turkey
关键词
Radiopharmaceutical; targeted radiotherapy; SARS-CoV-2; COVID-19; pandemic; coronavirus;
D O I
10.2174/1874471014666211011122250
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Coronavirus disease 2019 (COVID-19) pandemic, which has emerged in December 2019 in the city of Wuhan, China, has significantly affected healthcare systems and economies within a short timeframe. Treatment strategies offer alleviation of symptoms in the absence of commercially available specific antiviral agents. Within this context, the introduction of innovative therapeutic approaches against the SARS-CoV-2 virus is a critical need that should be addressed urgently. The anti-inflammatory effect of low dose irradiation has been proposed as a potential therapeutic strategy for COVID-19 pneumonia. Consideration of external beam irradiation for management of COVID-19 pneumonia has prompted the investigation of alternative methods of irradiation with potentially improved toxicity profiles. Theoretically, targeted radiotherapy may have several advantages over conventional external beam radiotherapy owing to the capability to deliver effective radiation doses without adverse irradiation effects. Since radionuclides are conjugated to targeting vectors, such as antibodies and cell surface receptor binding peptides, irradiation may be focused on targeted cells with optimal sparing of surrounding normal tissues. In the context of COVID-19 management, targeted irradiation is expected to compromise SARS-CoV-2 extracellular virions. Targeted radiotherapy may offer a viable means of combating against SARS-CoV-2 virus. There is room for improvement with the need for efficacy, feasibility, and toxicity studies. Although targeted radiotherapy itself may not achieve absolute eradication of virus or virus-infected cells, it may at least serve as a supplementary therapeutic strategy that could be utilized in combination with other antiviral treatments. Further investigations focusing on nuclear medicine, radiopharmaceuticals, and targeted radiotherapy strategies may pave the way for the development of efficacious antiviral treatments which may be utilized in the battle against the current COVID-19 pandemic.
引用
收藏
页码:93 / 95
页数:3
相关论文
共 15 条
[1]  
BAYLIN GJ, 1946, AM J ROENTGENOL, V55, P473
[2]   Passive antibody therapy for infectious diseases [J].
Casadevall, A ;
Dadachova, E ;
Pirofski, L .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (09) :695-703
[3]   Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins [J].
Dadachova, Ekaterina ;
Patel, Mahesh C. ;
Toussi, Sima ;
Apostolidis, Christos ;
Morgenstern, Alfred ;
Brechbiel, Martin W. ;
Gorny, Miroslaw K. ;
Zolla-Pazner, Susan ;
Casadevall, Arturo ;
Goldstein, Harris .
PLOS MEDICINE, 2006, 3 (11) :2094-2103
[4]   Future Vistas in Alpha Therapy of Infectious Diseases [J].
Dadachova, Ekaterina .
JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2019, 50 (04) :S49-S52
[5]   Radioimmunotherapy of Infectious Diseases [J].
Dadachova, Ekaterina ;
Casadevall, Arturo .
SEMINARS IN NUCLEAR MEDICINE, 2009, 39 (02) :146-153
[6]   Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS) [J].
Dhawan, Gaurav ;
Kapoor, Rachna ;
Dhawan, Rajiv ;
Singh, Ravinder ;
Monga, Bharat ;
Giordano, James ;
Calabrese, Edward J. .
RADIOTHERAPY AND ONCOLOGY, 2020, 147 :212-216
[7]  
DUBIN IN, 1946, AM J ROENTGENOL, V55, P478
[8]   Immunomodulation Through Low-Dose Radiation for Severe COVID-19: Lessons From the Past and New Developments [J].
Hanekamp, Yannic N. ;
Giordano, James ;
Hanekamp, Jaap C. ;
Khan, Mohammad K. ;
Limper, Maarten ;
Venema, Constantijn S. ;
Vergunst, Samuel D. ;
Verhoeff, Joost J. C. ;
Calabrese, Edward J. .
DOSE-RESPONSE, 2020, 18 (03)
[9]   Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19 [J].
Karthik, Kumaragurubaran ;
Senthilkumar, Tuticorin Maragatham Alagesan ;
Udhayavel, Shanmugasundaram ;
Raj, Gopal Dhinakar .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (12) :3055-3060
[10]   Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies [J].
Lee, Wen Shi ;
Wheatley, Adam K. ;
Kent, Stephen J. ;
DeKosky, Brandon J. .
NATURE MICROBIOLOGY, 2020, 5 (10) :1185-1191